[go: up one dir, main page]

AR053673A1 - Derivados de (1,2,4) - ditiazoli (di) , inductores de glutation - s- transferasa y nadph quinona oxido- reductasa , para profilaxis y tratamiento de condiciones adversas asociadas con citotoxicidad en general y apoptosis en particular - Google Patents

Derivados de (1,2,4) - ditiazoli (di) , inductores de glutation - s- transferasa y nadph quinona oxido- reductasa , para profilaxis y tratamiento de condiciones adversas asociadas con citotoxicidad en general y apoptosis en particular

Info

Publication number
AR053673A1
AR053673A1 ARP060100413A ARP060100413A AR053673A1 AR 053673 A1 AR053673 A1 AR 053673A1 AR P060100413 A ARP060100413 A AR P060100413A AR P060100413 A ARP060100413 A AR P060100413A AR 053673 A1 AR053673 A1 AR 053673A1
Authority
AR
Argentina
Prior art keywords
atom
4alkyl
unbranched
dialkyl
cyano
Prior art date
Application number
ARP060100413A
Other languages
English (en)
Inventor
Roelof W Feenstra
Hiskias G Keizer
Maria L Pras-Raves
Vliet Bernard J Van
Scharrenburg Gustaaf J M Van
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR053673A1 publication Critical patent/AR053673A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

También se refiere al uso de un compuesto descripto en la presente para la fabricacion de un medicamento util para la profilaxis y tratamiento de condiciones adversas asociadas con citotoxicidad en general y apoptosis en particular. Reivindicacion 2: Compuestos de la formula general (1) en donde las líneas punteadas entre el átomo de C numero 5 y sus átomos de N vecinos representan enlaces simples o dobles, con la condicion de que uno de los dos enlaces es un enlace simple y uno es un enlace doble, y con la condicion de que cuando el enlace doble está entre el átomo de C numero 5 y el átomo de N numero 4, R4 no existe y cuando el enlace doble está entre el átomo de C numero 5 y el átomo de N exo, R2no existe; R1, R2, R3 y R4 independientemente representan un grupo alquilo C1-4 ramificado o no ramificado, que contiene opcionalmente átomos de S o grupos sulfoxido, amida, cetona, tiocetona o sulfona, y está opcionalmente sustituido con halogeno, ciano, mono- o dialquil C1- 4amino, trifluorometilo, alcoxi C1-4 o hidroxilo, o R1 y R2 junto con el átomo de N al cual están unidos, forman un sistema de anillos de 4 a 8 miembros en el cual pueden estar presentes otros heteroátomos (sustituidos) elegidos de N, O y S, y el cual sistema de anillos puede estar opcionalmente sustituido con alquilo C1-4 ramificado o no ramificado, halogeno, ciano, mono- o dialquil C1-4amino, trifluorometilo, alcoxi C1-4 o hidroxilo lo el cual sistema de anillos contiene funciones amida, cetona, tiocetona, sulfona o sulfoxido, R3 representa H, alquilo C1-4 ramificado o no ramificado, que contiene opcionalmente átomos de S o grupos sulfoxido, amida, cetona, tiocetona o sulfona, y está opcionalmente sustituido con halogeno, ciano, mono- o dialquil C1-4amino, trifluorometilo, alcoxi C1-4, S-alquilo C1-4, SH o hidroxilo, o R3 representa un grupo arilo, opcionalmente sustituido con grupos alquilo C1-4 ramificado o no ramificado, arilo, alquil C1-4arilo, SH, S- alquilo C1-4, halogeno, ciano, mono- o dialquil C1-4amino, CF3, OCF3, SCF3, nitro, hidroxi o alcoxi C1-4, y los tautomeros, estereoisomeros N-oxidos de los mismos, así como las sales farmacologicamente aceptables, los hidratos y solvatos de dichos compuestos de formula (1) y sus tautomeros, estereoisomeros y N-oxidos.
ARP060100413A 2005-02-11 2006-02-06 Derivados de (1,2,4) - ditiazoli (di) , inductores de glutation - s- transferasa y nadph quinona oxido- reductasa , para profilaxis y tratamiento de condiciones adversas asociadas con citotoxicidad en general y apoptosis en particular AR053673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101004 2005-02-11

Publications (1)

Publication Number Publication Date
AR053673A1 true AR053673A1 (es) 2007-05-16

Family

ID=34938709

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100413A AR053673A1 (es) 2005-02-11 2006-02-06 Derivados de (1,2,4) - ditiazoli (di) , inductores de glutation - s- transferasa y nadph quinona oxido- reductasa , para profilaxis y tratamiento de condiciones adversas asociadas con citotoxicidad en general y apoptosis en particular

Country Status (14)

Country Link
EP (1) EP1851209B1 (es)
JP (1) JP2008530051A (es)
KR (1) KR20070107119A (es)
CN (1) CN101142199A (es)
AR (1) AR053673A1 (es)
AU (1) AU2006212209B2 (es)
BR (1) BRPI0607547A2 (es)
CA (1) CA2597523A1 (es)
MX (1) MX2007009695A (es)
RU (1) RU2397162C2 (es)
SA (1) SA06270010B1 (es)
TW (1) TW200640888A (es)
UA (1) UA94398C2 (es)
WO (1) WO2006084854A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018057989A1 (en) 2016-09-24 2018-03-29 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
JP6944690B2 (ja) * 2017-02-21 2021-10-06 株式会社アミンファーマ研究所 グルタチオン−ｓ−トランスフェラーゼ（ｇｓｔ）の発現増強剤
KR102254668B1 (ko) * 2019-04-16 2021-05-24 연세대학교 산학협력단 Gstt1 단백질 또는 이를 암호화하는 유전자를 유효성분으로 포함하는 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4144172A (en) * 1971-04-26 1973-10-25 Ortho Pharma Corp Inducing infertility in the male
JPS4930837B2 (es) * 1971-08-19 1974-08-16
JPS5581804A (en) * 1978-12-15 1980-06-20 Nippon Tokushu Noyaku Seizo Kk Acaricide and fungicide for agriculture and gardening
JP2685120B2 (ja) * 1994-07-20 1997-12-03 工業技術院長 ジチアゾリウム塩の製造方法

Also Published As

Publication number Publication date
EP1851209A2 (en) 2007-11-07
EP1851209B1 (en) 2012-05-30
AU2006212209A1 (en) 2006-08-17
KR20070107119A (ko) 2007-11-06
UA94398C2 (ru) 2011-05-10
CA2597523A1 (en) 2006-08-17
WO2006084854A3 (en) 2006-11-02
CN101142199A (zh) 2008-03-12
TW200640888A (en) 2006-12-01
RU2397162C2 (ru) 2010-08-20
RU2007133809A (ru) 2009-03-20
SA06270010B1 (ar) 2010-11-22
JP2008530051A (ja) 2008-08-07
BRPI0607547A2 (pt) 2010-04-06
WO2006084854A2 (en) 2006-08-17
MX2007009695A (es) 2007-11-12
AU2006212209B2 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR056964A1 (es) Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos
AR064444A1 (es) Derivados de los acidos amino- nicotinico y amino-isonicotinico. composiciones farmaceuticas
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR060401A1 (es) Derivados de cromen-2-ona
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
ES2668775T3 (es) Compuestos tetracíclicos
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
AR062109A1 (es) Derivados sustituidos de espirocetal y uso de los mismos como farmacos terapeuticos para la diabetes. composiciones farmaceuticas.
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR066583A1 (es) Derivados de 3,3-espiroindolinona
AR078786A1 (es) Derivados de la cromenona
AR044078A1 (es) Dihidroquinazolinas sustituidas
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20210398A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
BR112015019790A2 (pt) derivado de piridina monocíclica
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
AR059886A1 (es) Derivados de amidas como inhibidores de renina
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
RS53389B (en) PHARMACEUTICAL UNITS
AR059030A1 (es) Combinacion de derivados de triazina y estimuladores de la secrecion de insulina
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal